Background: Little evidence exists regarding the endpoint and optimum approach to
| INTRODUC TI ON
Catheter ablation of patients with long-standing persistent atrial fibrillation (LSPAF) is challenging, and little evidence is available regarding the endpoint and optimum approach to catheter ablation. 1 To improve ablation outcomes, adjunctive ablation methods in addition to pulmonary vein isolation (PVI) have been described. However, the STAR AF II trial revealed that the outcomes of LSPAF patients are not improved with either empiric linear ablation or complex fractionated atrial electrogram (CFAE) ablation. 2 Furthermore, which patients respond to PVI alone and which additional ablation approach improves the outcome remain unclear. In contrast, left atrium posterior wall isolation (PWI) and nonpulmonary vein (PV) trigger ablation were reported as additional ablation methods. [3] [4] [5] [6] However, few studies have so far examined the efficacy of these methods for LSPAF. In this study,
we examined the efficacy of PVI plus PWI with additional ablation of non-PV triggers induced by the administration of high-dose isoproterenol in patients with LSPAF.
| ME THODS

| Patient population and data collection
The subjects of this retrospective study were 159 consecutive patients who underwent catheter ablation for drug-refractory LSPAF at our institution from January 2012 to June 2016. LSPAF was defined as continuous AF lasting ≥12 months. Of the 159 patients, 2 with less than 3 months' follow-up after the last ablation procedure and 2 who received antiarrhythmic drugs (AADs) for ventricular arrhythmia were excluded, leaving 155 patients. All patients gave their written informed consent for the ablation procedure and enrollment in our ablation registry. This study was approved by our institutional review board.
| Ablation protocol during the initial procedure
AADs were discontinued at least five half-lives before the procedure. and initial-group C, unmappable non-PV triggers were induced.
Patients with both mappable and unmappable non-PV triggers were classified into initial-group C.
| Ablation protocol during repeat procedures
The patients experiencing recurrence of atrial tachyarrhythmias, such as AF and atrial tachycardia, after a blanking period (within 3 months after the last procedure) were encouraged to undergo a repeat procedure. The primary step in repeat procedures for recurrent atrial tachyarrhythmias was the assessment of reconnection of the PV or PW. All identified conduction gaps were ablated to achieve complete PVI plus PWI. If sustained atrial tachycardias were identified, we first performed mapping and ablation for them using acti- 
| Patient follow-up and the primary outcome
After ablation, anticoagulants were continued for 3 months or longer depending on the CHADS2 score. AADs were typically discontinued within 3 months after ablation if recurrence of atrial tachyarrhythmias was absent. All patients were scheduled to visit our hospital at 1, 3, 6, 9, and 12 months after the procedure and then every 6 months thereafter. A 12-lead electrogram (ECG) was obtained at each follow-up point. Twenty-four-hour Holter monitoring was performed at 3 and 12 months and 3 and 5 years after the procedure. This study's primary outcome was freedom from recurrence of atrial tachyarrhythmias (≥30 seconds) without AADs at 1 year after the last procedure. Episodes of atrial tachyarrhythmia only within the blanking period were not considered recurrences.
| Statistical analysis
Continuous variables are expressed as means with standard deviations or median with the interquartile range (Q1-Q3) as appropriate. 
| RE SULTS
| Patients' characteristics
Patients' characteristics are shown in Table 1 . Of the 155 patients, there were 124 men (80%) with a mean age of 61 ± 9 years old. The mean LA diameter was 42 ± 6 mm. The median duration of persistent AF was 36 (Q1-Q3: 21-48) months.
| Ablation procedure
During the initial procedure, PVI plus PWI was achieved in 146 (94%)
patients. In the remaining 9 (6%) patients, PVI was completed but not 
Initial-group B (N = 41)
Initial-group C (N = 9) P-Value 
| Characteristics and the ablation outcome in each group
We compared the baseline characteristics of each group after the initial procedure (Table 1) and after multiple procedures. After the initial procedure, the AF duration in initial-group C was significantly longer than that in initial-group A (P = 0.004) and initial-group B (P = 0.03). After multiple procedures, the AF duration in final-group C was significantly longer than that in final-group A (P < 0.001) and final-group B (P < 0.001). The LA diameter in final-group C was significantly larger than that in final-group A (P = 0.04). (95% CI, 72-94), and 53% in final-group C (95% CI, 28-72). After multiple procedures, the outcome of final-group C was significantly lower than that of final-group A (P < 0.001) and final-group B (P < 0.001).
| Procedure time and complications
The median procedure time was 183 (Q1-Q3; 155-220) minutes.
Complications occurred in 7 of 226 (3%) procedures; 4 (2%) patients had pericardial effusion that required percutaneous drainage, 2 (1%) had gastroparesis, and 1 (0.4%) patient had an esophageal ulcer. All patients were conservatively treated without long-term sequelae.
| D ISCUSS I ON
| Main findings
In this study, we demonstrated the efficacy of PVI plus PWI and additional ablation of non-PV triggers induced by the administration of highdose isoproterenol for patients with LSPAF. The 1-year freedom from atrial tachyarrhythmia recurrence rate without AAD was 65% after a single procedure, which improved to 86% after multiple procedures (mean 1.5 per patient). Of note, the ablation outcomes were highly dependent F I G U R E 3 Flow chart describing the outcome after each procedure. AAD: antiarrhythmic drug; AT: atrial tachycardia; SR: sinus rhythm; PAF: paroxysmal atrial fibrillation; Per AF: persistent atrial fibrillation on the presence of non-PV triggers. In approximately 60% of the LSPAF patients (group A), non-PV triggers were not induced using high-dose isoproterenol infusion, and PVI plus PWI alone achieved good outcomes (73% after a single procedure, 93% after multiple procedures). In approximately 30% of the patients (group B), mappable non-PV triggers were elicited, and the outcome of ablation of mappable non-PV triggers in addition to PVI plus PWI was 56% after a single procedure, which increased to 86% after multiple procedures. In contrast, approximately 10% of the patients (group C) had unmappable non-PV triggers and a poor outcome (11% after a single procedure, 53% after multiple procedures).
| Efficacy of PVI plus PWI for LSPAF
The efficacy of PVI for patients with paroxysmal AF (PAF) is wellestablished. In contrast, catheter ablation for LSPAF patients remains challenging. 1 Although some adjunctive ablation methods have been proposed, [8] [9] [10] the optimum approach has not been elucidated.
A recent meta-analysis reported that additional substrate ablation is associated with a worse outcome than PVI alone, although the singleprocedure success rate of pulmonary vein antrum isolation alone for LSPAF is 57%. 11 In contrast, some studies reported the efficacy and ranging from 42% to 50% at almost 2 years after a single procedure, which improves to 60% to 63% after repeat procedures (mean 1.4 per patient). 12 As an explanation for these results, several studies have suggested that the LAPW plays an important role in initiating and maintaining AF. [13] [14] [15] [16] However, there is little evidence regarding which LSPAF patients achieve sufficiently good outcomes from PVI plus PWI alone. Therefore, the endpoint of catheter ablation of LSPAF patients has never been determined. Several studies have proposed non-inducibility of AF by high-dose isoproterenol as a useful endpoint for catheter ablation in PAF patients. 5, 17, 18 However, whether or not the same applies to LSPAF patients has been unclear. Our findings have shown that durable PVI plus PWI alone is sufficient therapy for patients without non-PV triggers induced by high-dose isoproterenol, and non-inducibility of non-PV triggers by high-dose isoproterenol is a useful endpoint for catheter ablation, even in LSPAF patients.
| Additional non-PV trigger ablation for LSPAF patients
The benefits of ablating non-PV triggers to improve the arrhythmia-free survival for PAF have been well-established in previous studies. 5, 19 In addition, a retrospective study on PVI and additional non-PV trigger ablation reported that non-PV triggers were elicited in 18% of patients either during the initial or repeat procedures, and 50% of patients maintained a normal sinus rhythm without AADs after a mean 1.3 procedures and a mean follow-up period of 39 months. 6 In contrast, it has been reported that only 30% of non-PV triggers were able to be ablated because of difficulties in locating them, although the patients in whom all non-PV triggers were eliminated had significantly better outcomes than those in whom non-PV triggers could not be ablated.
20
The prevalence of non-PV triggers in our study was higher than in previous studies. This difference might be explained by the definition of non-PV triggers, as ectopic beats initiating not only AF or atrial tachycardia but also frequent and repetitive atrial premature beats (>3 beats) were considered non-PV triggers in our study. The outcome of group B was significantly worse than that of group A after a single procedure but became comparable to that of group A after multiple procedures. Although the performance of re-PVI plus PWI as repeat procedures contributed to the improvement in the outcome after multiple procedures, our results indicate that it was difficult to induce and eliminate all non-PV triggers in a single procedure, suggesting the importance of repeat non-PV trigger ablation across multiple procedures. Careful ablation of mappable non-PV triggers may reduce the rate of ineffective extensive ablation and improve the arrhythmia-free survival. However, the presence of unmappable non-PV triggers significantly increases the rate of atrial tachyarrhythmia recurrence.
| Study limitations
This was a retrospective observational study; however, our approach to LSPAF ablation was consistent with the endpoint of PVI plus PWI with the elimination of non-PV triggers using high-dose isoproterenol infusion. Although the outcomes of patients who underwent PVI plus PWI with or without mappable non-PV triggers were comparable after multiple procedures, the efficacy of additional non-PV trigger ablation was uncertain because of the absence of a control group that underwent PVI plus PWI because provocation and ablation of non-PV triggers were not performed. The median LA diameter in our study was not as large as in some previous studies about LSPAF patients F I G U R E 6 Freedom from recurrence of atrial tachyarrhythmias without antiarrhythmic drugs after multiple procedures. ATA: atrial tachyarrhythmias; AAD: antiarrhythmic drugs but was larger than that described for a healthy Japanese population and in a previous study of Japanese paroxysmal AF patients. This may be because of the fact that Japanese hearts are relatively small. 21 In our study, adjunctive CFAE ablation may have affected the ablation outcome, although it was performed not empirically but only if non-PV triggers were unmappable. Further studies with a control group of patients with inducible non-PV triggers who did not undergo ablation will be required to confirm that ablation of non-PV triggers has an incremental benefit over PVI plus PWI.
| CON CLUS ION
In approximately 60% of LSPAF patients, non-PV triggers were not induced by high-dose isoproterenol infusion, and PVI plus PWI alone achieved good outcomes. Noninducibility of non-PV triggers by highdose isoproterenol is a useful endpoint for catheter ablation, even in LSPAF patients. Although the inducibility of non-PV triggers after PVI plus PWI was associated with the recurrence of atrial tachyarrhythmias, the ablation of mappable non-PV triggers may improve the outcome after multiple procedures. However, the presence of unmappable non-PV triggers was significantly associated with poor outcomes.
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